KalVista Pharmaceuticals (KALV) Profit After Tax (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Profit After Tax data on file, last reported at -$61.3 million in Q3 2025.

• For the quarter ending Q3 2025, Profit After Tax fell 51.49% year-over-year to -$61.3 million; the trailing twelve-month figure through Jul 2025 stood at -$197.9 million (down 39.59% YoY), and the FY2025 full-year result was -$185.2 million, down 45.72% from the prior year.
• Profit After Tax retreated to -$61.3 million in Q3 2025, from -$54.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$10.0 million in Q1 2021 to a low of -$61.3 million in Q3 2025.
• A 5-year average of -$29.2 million and a median of -$25.9 million in 2022 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax tumbled 123.6% in 2022 and rose 13.13% in 2023, its largest moves.
• Tracing KALV's Profit After Tax over 5 years: stood at -$19.6 million in 2021, then slipped by 13.27% to -$22.3 million in 2022, then decreased by 24.23% to -$27.6 million in 2023, then slumped by 52.87% to -$42.3 million in 2024, then plunged by 44.95% to -$61.3 million in 2025.
• Business Quant data shows KALV's Profit After Tax at -$61.3 million in Q3 2025, -$54.0 million in Q2 2025, and -$42.3 million in Q4 2024.